Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance.
Gaetano ScaramuzzoFrancesco NuceraAlessio AsmundoRoberto MessinaMatilde MariFederica MontanaroMatt D JohansenFrancesco MonacoGuido FaddaGiovanni TuccariNicole G HansbroPhilip Michael HansbroTrevor T HanselIssssswan M AdcockAntonio DavidPaul KirkhamGaetano CaramoriCarlo Alberto VoltaSpadaro SavinoPublished in: Journal of inflammation (London, England) (2023)
The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection can be asymptomatic or cause a disease (COVID-19) characterized by different levels of severity. The main cause of severe COVID-19 and death is represented by acute (or acute on chronic) respiratory failure and acute respiratory distress syndrome (ARDS), often requiring hospital admission and ventilator support.The molecular pathogenesis of COVID-19-related ARDS (by now termed c-ARDS) is still poorly understood. In this review we will discuss the genetic susceptibility to COVID-19, the pathogenesis and the local and systemic biomarkers correlated with c-ARDS and the therapeutic options that target the cell signalling pathways of c-ARDS.
Keyphrases
- acute respiratory distress syndrome
- respiratory failure
- extracorporeal membrane oxygenation
- mechanical ventilation
- coronavirus disease
- sars cov
- respiratory syndrome coronavirus
- intensive care unit
- drug induced
- liver failure
- emergency department
- healthcare
- stem cells
- mesenchymal stem cells
- early onset
- single cell
- cell therapy
- genome wide
- acute care
- adverse drug